Outlook Therapeutics Inc (NASDAQ:OTLK) finished Wednesday with a subtraction of $0.0 to close at $0.22, a downside of -1.32 percent. An average of 3,051,680 shares of common stock have been traded in the last five days. There was a gain of $0.0018 in the past week, and it reached a new high 13 times over the past 12 months. The last 20 days have seen an average of 14,666,950 shares traded, while the 50-day average volume stands at 6,973,294.
OTLK stock has decreased by -83.03% in the last month. The company shares reached their 1-month lowest point of $0.2002 on 09/08/23. With the stock rallying to its 52-week high on 06/06/23, shares of the company touched a low of $0.20 and a high of $2.03 in 52 weeks. It has reached a new high 11 times so far this year and lost -79.89% or -$0.8628 in price. In spite of this, the price is down -89.30% from the 52-week high.
Insider Transactions
OTLK stock investors should be aware that Outlook Therapeutics Inc (OTLK) stock had its last reported insider trading activity 161 days ago on Apr 20. In this transaction, the insider spent $590,200. Chief Commercial Officer, Evanson Jeff, disposed of 267,000 shares at a price of $1.11 on Jan 20. The insider now owns more than $296,370 worth of shares. Prior to that, Chief Commercial Officer Evanson Jeff went on to Sale 103,255 shares at $1.22 each on Jan 19. An amount of $125,971 was transacted.
Financial Health
The quick ratio of Outlook Therapeutics Inc for the three months ended June 29 was 0.86, and the current ratio was 0.86, indicating that the company is not able to meet its debt obligations. Its gross profit as reported stood at $63.07 million.
Earnings Surprise
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$20.68 million in the quarter, while revenues of -$6.65 million were grew 15.18%. The analyst consensus anticipated Outlook Therapeutics Inc’s latest quarter earnings to come in at -$0.05 per share, but it turned out to be -$0.08, a -60.00% surprise. For the quarter, EBITDA amounted to -$18.13 million. Shareholders own equity worth $260.25 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Outlook Therapeutics Inc (OTLK) price momentum. RSI 9-day as of the close on 27 September was 23.36%, suggesting the stock is oversold, with historical volatility in this time frame at 55.44%.
As of today, OTLK’s price is $0.2138 +0.84% or $0.0018 from its 5-day moving average. OTLK is currently trading -84.60% lower than its 20-day SMA and -80.43% lower than its 100-day SMA. However, the stock’s current price level is -87.52% below the SMA50 and -78.50% below the SMA200.
The stochastic %K and %D were 28.60% and 23.42%, respectively, and the average true range (ATR) was 0.0376. With the 14-day stochastic at 29.11% and the average true range at 0.0578, the RSI (14) stands at 22.57%. The stock has reached 0.0016 on the 9-day MACD Oscillator while the 14-day reading was at 0.0003.
Analyst Ratings
H.C. Wainwright downgraded Outlook Therapeutics Inc (NASDAQ: OTLK) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as a Buy. The consensus rating for Outlook Therapeutics Inc (OTLK) among analysts is Hold. According to current brokerage recommendations, 0 brokerage firms advise that investors sell OTLK, while 7 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.
What is OTLK’s price target for the next 12 months?
Analysts predict a range of price targets between $1.00 and $10.00, with a median target of $1.25. Taking a look at these predictions, the average price target given by analysts for Outlook Therapeutics Inc (OTLK) stock is $3.75.
